Skip to content

Study · Not a test of the peptide alone · 2026

3 results

Déjà vu! A Case of Recurrent Metabolic Dysfunction-Associated Steatohepatitis 70 Days After Liver Transplantation.

Still M, Gettelfinger A, Akinditan V, Syed A, Eggert A, Thornsberry T, Ciricillo J, Sharma D, Yeboah-Korang A

ACG case reports journal10 Jul 2026

PMID42433972 (opens in a new tab)PMCIDPMC13354390 (opens in a new tab)DOI10.14309/crj.0000000000002232 (opens in a new tab)PepBankPUB-42433972
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a liver transplant recipient with recurrent MASH, a multimodal metabolic intervention that included semaglutide reduced steatosis to 30%.

    In plain wordsIn one liver transplant patient, a treatment package that included semaglutide came with lower liver fat. The effect of semaglutide alone is unknown.

    Peptide
    Semaglutide
    Outcome
    DecreaseHepatic steatosis
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver

    Measurements

    Steatosis
    30%
    after intervention

    Source sentences

    Summary
    Multimodal intervention, including semaglutide, resulted in histologic improvement (steatosis reduced to 30%, ballooning resolved) with sustained biochemical normalization.
    1 context sentence
    Summary · context
    We present a 40-year-old woman with obesity and remote kidney transplant who underwent liver transplantation for MASH cirrhosis. At 10 weeks posttransplant, she developed acute cellular rejection and 68% steatosis, progressing to >95% steatohepatitis with F1 fibrosis within 6 days on corticosteroid treatment.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a liver transplant recipient with recurrent MASH, a multimodal metabolic intervention that included semaglutide resolved ballooning.

    In plain wordsIn one liver transplant patient, a treatment package that included semaglutide came with resolved liver cell ballooning. The effect of semaglutide alone is unknown.

    Peptide
    Semaglutide
    Outcome
    DecreaseHepatocyte ballooning
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    Multimodal intervention, including semaglutide, resulted in histologic improvement (steatosis reduced to 30%, ballooning resolved) with sustained biochemical normalization.
    1 context sentence
    Summary · context
    We present a 40-year-old woman with obesity and remote kidney transplant who underwent liver transplantation for MASH cirrhosis. At 10 weeks posttransplant, she developed acute cellular rejection and 68% steatosis, progressing to >95% steatohepatitis with F1 fibrosis within 6 days on corticosteroid treatment.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a liver transplant recipient with recurrent MASH, a multimodal metabolic intervention that included semaglutide was followed by sustained biochemical normalization.

    In plain wordsIn one liver transplant patient, a treatment package that included semaglutide came with normal blood liver tests. The effect of semaglutide alone is unknown.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedBiochemical liver tests
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    with sustained biochemical normalization.
    1 context sentence
    Summary · context
    We present a 40-year-old woman with obesity and remote kidney transplant who underwent liver transplantation for MASH cirrhosis. At 10 weeks posttransplant, she developed acute cellular rejection and 68% steatosis, progressing to >95% steatohepatitis with F1 fibrosis within 6 days on corticosteroid treatment.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.